INTRODUCTION {#s1}
============

In 2012, more than 400,000 new cases of bladder cancer (BC) were diagnosed and 165,000 patients died worldwide \[[@R1]\]. As for the prevalence of BC, men are three times more frequently diagnosed with BC than women \[[@R2]\]. The reasons for this disparity between sexes are not fully understood. BC is pathologically classified into two groups: non-muscle-invasive BC (NMIBC) and muscle-invasive BC (MIBC). Most BC patients (approximately 50%--80%) are diagnosed with NMIBC and this disease can be treated by removing the tumor by transurethral approaches \[[@R3]\]. In NMIBC, disease may recur, and some patients (approximately 25%) progress to MIBC \[[@R3]\]. Patients with advanced BC are generally treated with combination chemotherapy (gemcitabine and cisplatin), but progression-free survival is of limited duration \[[@R4]\]. Therefore, it is important to elucidate the molecular mechanisms of recurrence and invasiveness of BC cells to develop new treatment strategies.

The discovery of non-coding RNA in the human genome changed approaches in cancer research \[[@R5], [@R6]\]. Molecular mechanisms of post transcriptional gene regulation by protein-coding RNA/non-coding RNA networks are being studied on a genome-wide scale. MicroRNA (miRNA) is a class of small non-coding RNAs, and they are known to be involved in the repression or degradation of target RNA transcripts in a sequence-dependent manner \[[@R7]\]. A single miRNA can regulate thousands of target transcripts, and more than 60% of protein-coding genes may be influenced by miRNAs \[[@R8], [@R9]\]. Accumulating evidence indicates that aberrantly expressed miRNAs disturb normally regulated RNA networks, leading to pathologic responses in cancer cells \[[@R6]\]. Strategies to identify aberrant expression of miRNA-mediated cancer pathways are being developed as a new direction in cancer research in the post genome sequencing era.

To seek out differentially expressed miRNAs in BC cells, we used BC clinical specimens to establish deep sequencing-based miRNA expression signatures \[[@R10]\]. In general, the guide-strand RNA from duplex miRNA is retained to direct recruitment of the RNA induced silencing complex (RISC) to target messenger RNAs, whereas the passenger-strand RNA is degraded \[[@R11]--[@R13]\]. Recently, we revealed that both strands of *microRNA* (*miR*)*-144-5p* and *miR-144-3p* derived from *pre-miR-144* acted as tumor suppressors in BC cells \[[@R14]\]. Moreover, *miR-144-5p* (passenger-strand) directly targeted *cyclin E1* and *E2* in BC cells, suggesting that the passenger-strand of miRNA has a physiological role in cells \[[@R14]\].

In this study, we focused on *miR-145-5p* and *miR-145-3p* because these miRNAs were significantly downregulated in BC cells as determined in our deep sequencing signature \[[@R10]\]. It is well known that *miR- 145- 5p* functions as a tumor suppressor in several types of cancer, including BC \[[@R15]\]. However, the role of *miR-145-3p* on cancer cells is still ambiguous. The aims of the present study were to investigate the anti-tumor effects of *miR-145-3p* as well as *miR-145-5p*, and to determine the BC oncogenic pathways and target genes regulated by these miRNAs. The discovery that *miR- 145- 5p* and *miR-145-3p* coordinately regulate pathways and targets provides new insight into the mechanisms of BC progression and metastasis.

RESULTS {#s2}
=======

The expression levels of *miR-145-5p* and *miR-145-3p* in BC specimens and cell lines {#s2_1}
-------------------------------------------------------------------------------------

We evaluated the expression levels of *miR-145-5p* and *miR-145-3p* in BC tissues (*n* = 69), normal bladder epithelia (NBE) (*n* = 12), and two BC cell lines (T24 and BOY). The expression levels of *miR-145-5p* and *miR- 145- 3p* were significantly lower in tumor tissues and BC cell lines compared with NBE (Figure [1A](#F1){ref-type="fig"}). Spearman\'s rank test showed a positive correlation between the expression of these miRNAs (*r* = 0.986 and *P* \< 0.0001) (Figure [1B](#F1){ref-type="fig"}). On the other hand, there were no significant relationships between any of the clinicopathological parameters (i.e., tumor grade, stage, metastasis, or survival rate) and the expression levels of *miR-145-5p* and *miR-145-3p* (data not shown).

![The expression levels of *miR-145-5p* and *miR-145-3p*, and their effects in BC cells\
(**A**) Expression levels of *miR- 145- 5p* and *miR-145-3p* in clinical specimens and BC cell lines were determined by qRT-PCR. Data were normalized to *RNU48* expression. (**B**) Correlation of *miR-145-5p* and *miR-145-3p* expression. (**C**) Cell growth was determined by XTT assays 72 hours after transfection with 10 nM *miR-145-5p* or *miR-145-3p*. \**P* \< 0.0001. (**D**) Cell migration activity was determined by the wound-healing assays. \**P* \< 0.0001. (**E**) Cell invasion activity was determined using Matrigel invasion assays. \**P* \< 0.0001.](oncotarget-07-28460-g001){#F1}

Effect of restoring *miR-145-5p* or *miR-145- 3p* expression on cell growth, migration, and invasion in BC cell lines {#s2_2}
---------------------------------------------------------------------------------------------------------------------

We performed gain-of-function studies using transfection of these miRNAs to investigate their functional roles. XTT, cell migration, and invasion assays demonstrated that cell proliferation, cell migration, and cell invasion were significantly inhibited in *miR-145-5p* and *miR-145-3p* transfectants in comparison with mock or miR-control transfectants (each *P* \< 0.0001, Figure [1C](#F1){ref-type="fig"}, [1D](#F1){ref-type="fig"}, and [1E](#F1){ref-type="fig"}). These results suggested that *miR-145-3p* as well as *miR-145-5p* could have a tumor suppressive function in BC cells.

To investigate the synergistic effects of *miR- 145- 5p* and *miR-145-3p*, we performed proliferation, migration, and invasion assays with co-transfection of *miR- 145-5p* and *miR-145-3p* in BC cells (T24 and BOY), but they did not show synergistic effects of these miRNAs transfection ([Supplementary Figure 1](#SD1){ref-type="supplementary-material"}).

Effects of *miR-145-5p* and *miR-145-3p* transfection on apoptosis and cell cycle in BC cell lines {#s2_3}
--------------------------------------------------------------------------------------------------

Because *miR-145-5p* and *miR-145-3p* transfection strongly inhibited cell proliferation in BC cell lines, we hypothesized that these miRNAs may induce apoptosis. Hence, we performed flow cytometric analyses to determine the number of apoptotic cells following restoration of *miR- 145-5p* or *miR-145-3p* expression.

The apoptotic cell numbers (apoptotic and early apoptotic cells) were significantly larger in *miR-145-5p* or *miR-145-3p* transfectants than in mock or miR-control transfectants (Figure [2A](#F2){ref-type="fig"} and [2C](#F2){ref-type="fig"}). Western blot analyses showed that cleaved PARP expression was significantly increased in *miR-145-5p* or *miR-145-3p* transfectants compared with mock or miR-control transfectants (Figure [2B](#F2){ref-type="fig"} and [2D](#F2){ref-type="fig"}).

![Effects of *miR-145-5p* and *miR-145-3p* on apoptosis\
(**A**, **C**) Apoptosis assays were carried out using flow cytometry. Early apoptotic cells are in area R4 and apoptotic cells are in area R2. The normalized ratios of apoptotic cells are shown in the histograms. Cycloheximide (2 μg/mL) was used as positive control. \**P* = 0.0266 and \*\**P* \< 0.0001. (**B**, **D**) Western blot analyses for apoptotic markers (cleaved PARP) in BC cell lines. GAPDH was used as a loading control.](oncotarget-07-28460-g002){#F2}

We also investigated the cell cycle assays using *miR-145-5p* and *miR-145-3p* transfectants. The fraction of cells in the G2/M phase was significantly larger in *miR-145-5p* and *miR-145-3p* transfectants in T24 cells in comparison with mock or miR-control transfectants ([Supplementary Figure 2](#SD1){ref-type="supplementary-material"}). In contrast, *miR-145-5p* and *miR-145-3p* transfection induced cell cycle arrest at the G1 phase in BOY cells ([Supplementary Figure 2](#SD1){ref-type="supplementary-material"}). The reason why the cell cycle arrest (G2 arrest in T24 and G1 arrest in BOY) varies according to a cell types is a future problem.

Identification of common target genes regulated by *miR-145-5p* and *miR-145-3p* in BC cells {#s2_4}
--------------------------------------------------------------------------------------------

To gain further insight into the molecular mechanisms and pathways regulated by tumor suppressive *miR-145-5p* and *miR-145-3p* in BC cells, we used a combination of *in silico* analyses and gene expression analyses. Figure [3](#F3){ref-type="fig"} shows our strategy to narrow down the common target genes of *miR-145-5p* and *miR-145-3p*.

![Flow chart illustrates the strategy for analysis of *miR-145-5p* and *miR-145-3p* target genes\
A total of 4,555 and 6,295 downregulated genes in expression analysis of *miR-145-5p* and *miR-145-3p* transfected BC cell lines, respectively, (T24 and BOY) were selected as putative target genes. Next we merged the data of those selected genes and the [microRNA.org](http://microrna.org/) database. The analyses showed 398 common putative target genes between *miR-145-5p* and *miR-145-3p*. We then analyzed gene expression with available GEO data sets (GSE11783 + GSE31684). The analyses showed that 79 genes were significantly upregulated in BC specimens compared with NBE.](oncotarget-07-28460-g003){#F3}

In gene expression analyses, a total of 4,555 and 6,295 genes were downregulated in *miR-145-5p* and *miR- 145-3p* transfectants, respectively, in comparison with control transfectants (Gene Expression Omnibus (GEO), accession number: GSE66498). Of those downregulated genes, 1,735 and 1,680 genes, respectively, had putative binding sites for *miR-145-5p* and *miR-145- 3p* in their 3′ untranslated regions (UTRs) according to the [microRNA.org](http://microrna.org/) database. We found that there were 398 common genes targeted by both miRNAs, and among them, we ultimately identified 79 genes that were upregulated in the clinical BC samples from the GEO (accession numbers: GSE11783, GSE31684) (Table [1](#T1){ref-type="table"}). We subsequently focused on the ubiquitin-like with PHD and ring finger domains 1 (*UHRF1*) gene because it was the top ranked gene in the list.

###### Highly expressed genes putatively regulated by *miR-145-5p* and *miR-145-3p*

  ------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  Entrez Gene ID   Gene Symbol   Description                                                                                            Genomic location   Gene Expression Omnibus (GSE11783 + GSE31684)   Expression in *miR-145-5p*transfectant (Log~2~ FC)   Expression in *miR-145-3p*transfectant (Log~2~ FC)                              
  ---------------- ------------- ------------------------------------------------------------------------------------------------------ ------------------ ----------------------------------------------- ---------------------------------------------------- ---------------------------------------------------- -------- -------- -------- --------
  29128            *UHRF1*       ubiquitin-like with PHD and ring finger domains 1                                                      19p13.3            up                                              4.984                                                1.049E-03                                            −0.041   −0.274   −0.334   −0.901

  54972            *TMEM132A*    transmembrane protein 132A                                                                             11q12.2            up                                              3.458                                                1.049E-03                                            −0.006   −0.087   −0.178   −0.140

  4288             *MKI67*       marker of proliferation Ki-67                                                                          10q26.2            up                                              3.182                                                1.049E-03                                            −0.070   −0.022   −0.609   −0.872

  1111             *CHEK1*       checkpoint kinase 1                                                                                    11q24.2            up                                              2.841                                                1.049E-03                                            −0.354   −0.204   −0.426   −0.583

  25886            *POC1A*       POC1 centriolar protein A                                                                              3p21.2             up                                              2.354                                                1.049E-03                                            −0.146   −0.194   −0.251   −0.161

  400745           *SH2D5*       SH2 domain containing 5                                                                                1p36.12            up                                              2.299                                                1.049E-03                                            −0.512   −0.075   −0.136   −0.038

  55215            *FANCI*       Fanconi anemia, complementation group I                                                                15q26.1            up                                              2.188                                                1.049E-03                                            −0.031   −0.079   −0.281   −0.320

  51512            *GTSE1*       G-2 and S-phase expressed 1                                                                            22q13.31           up                                              2.147                                                1.049E-03                                            −0.028   −0.149   −0.713   −0.209

  157570           *ESCO2*       establishment of sister chromatid cohesion N-acetyltransferase 2                                       8p21.1             up                                              2.028                                                1.049E-03                                            −0.441   −0.352   −0.585   −0.166

  2175             *FANCA*       Fanconi anemia, complementation group A                                                                16q24.3            up                                              1.877                                                1.049E-03                                            −0.017   −0.166   −0.412   −0.532

  6624             *FSCN1*       fascin homolog 1, actin-bundling protein (Strongylocentrotus purpuratus)                               7p22.1             up                                              1.829                                                2.942E-03                                            −2.899   −0.732   −0.175   −1.133

  22979            *EFR3B*       EFR3 homolog B (S. cerevisiae)                                                                         2p23.3             up                                              1.803                                                1.247E-03                                            −0.312   −0.033   −1.189   −1.625

  3918             *LAMC2*       laminin, gamma 2                                                                                       1q25.3             up                                              1.797                                                1.791E-02                                            −0.839   −0.707   −0.125   −0.608

  8349             *HIST2H2BE*   histone cluster 2, H2be                                                                                1q21.2             up                                              1.764                                                1.524E-03                                            −0.266   −0.149   −0.524   −0.170

  9455             *HOMER2*      homer homolog 2 (Drosophila)                                                                           15q25.2            up                                              1.706                                                2.526E-03                                            −0.360   −0.278   −0.132   −0.305

  25902            *MTHFD1L*     methylenetetrahydrofolate dehydrogenase (NADP+ dependent) 1-like                                       6q25.1             up                                              1.611                                                1.049E-03                                            −0.307   −0.024   −0.617   −0.505

  55732            *C1orf112*    chromosome 1 open reading frame 112                                                                    1q24.2             up                                              1.461                                                1.685E-03                                            −0.099   −0.147   −0.030   −0.132

  388389           *CCDC103*     coiled-coil domain containing 103                                                                      17q21.31           up                                              1.390                                                3.290E-02                                            −0.327   −0.266   −2.471   −1.838

  6566             *SLC16A1*     solute carrier family 16 (monocarboxylate transporter), member 1                                       1p13.2             up                                              1.359                                                3.893E-02                                            −0.229   −0.137   −0.759   −1.259

  23178            *PASK*        PAS domain containing serine/threonine kinase                                                          2q37.3             up                                              1.333                                                1.058E-03                                            −0.016   −0.001   −0.218   −0.443

  5426             *POLE*        polymerase (DNA directed), epsilon, catalytic subunit                                                  12q24.33           up                                              1.241                                                1.247E-03                                            −0.094   −0.424   −0.295   −0.051

  55379            *LRRC59*      leucine rich repeat containing 59                                                                      17q21.33           up                                              1.233                                                1.049E-03                                            −0.155   −0.198   −0.289   −0.283

  6715             *SRD5A1*      steroid-5-alpha-reductase, alpha polypeptide 1 (3-oxo-5 alpha-steroid delta 4-dehydrogenase alpha 1)   5p15.31            up                                              1.170                                                5.069E-03                                            −0.329   −0.018   −0.823   −0.837

  4602             *MYB*         v-myb avian myeloblastosis viral oncogene homolog                                                      6q23.3             up                                              1.160                                                4.501E-03                                            −0.105   −0.337   −0.111   −1.418

  8940             *TOP3B*       topoisomerase (DNA) III beta                                                                           22q11.22           up                                              1.157                                                9.078E-03                                            −0.108   −0.021   −0.840   −1.150

  64768            *IPPK*        inositol 1,3,4,5,6-pentakisphosphate 2-kinase                                                          9q22.31            up                                              1.153                                                1.072E-03                                            −0.526   −0.102   −0.630   −0.296

  9266             *CYTH2*       cytohesin 2                                                                                            19q13.33           up                                              1.127                                                1.049E-03                                            −0.226   −0.104   −0.598   −0.377

  221468           *TMEM217*     transmembrane protein 217                                                                              6p21.2             up                                              1.081                                                4.734E-02                                            −0.049   −0.008   −0.033   −0.337

  25859            *PART1*       prostate androgen-regulated transcript 1 (non-protein coding)                                          5q12.1             up                                              1.025                                                4.873E-03                                            −0.144   −0.212   −0.097   −0.694

  8566             *PDXK*        pyridoxal (pyridoxine, vitamin B6) kinase                                                              21q22.3            up                                              1.014                                                1.316E-03                                            −0.039   −0.842   −0.567   −0.558

  11072            *DUSP14*      dual specificity phosphatase 14                                                                        17q12              up                                              1.008                                                2.440E-03                                            −0.126   −0.092   −0.924   −1.020

  23516            *SLC39A14*    solute carrier family 39 (zinc transporter), member 14                                                 8p21.3             up                                              0.999                                                3.435E-03                                            −0.540   −0.216   −2.083   −1.548

  85414            *SLC45A3*     solute carrier family 45, member 3                                                                     1q32.1             up                                              0.977                                                3.435E-03                                            −0.578   −0.086   −0.782   −0.505

  1163             *CKS1B*       CDC28 protein kinase regulatory subunit 1B                                                             1q21.3             up                                              0.941                                                1.857E-02                                            −0.370   −0.229   −0.678   −0.802

  79929            *MAP6D1*      MAP6 domain containing 1                                                                               3q27.1             up                                              0.927                                                1.093E-03                                            −0.135   −0.210   −0.928   −0.529

  65985            *AACS*        acetoacetyl-CoA synthetase                                                                             12q24.31           up                                              0.919                                                1.058E-03                                            −0.555   −0.367   −0.816   −0.798

  1263             *PLK3*        polo-like kinase 3                                                                                     1p34.1             up                                              0.910                                                1.685E-03                                            −0.229   −0.092   −1.766   −2.103

  64785            *GINS3*       GINS complex subunit 3 (Psf3 homolog)                                                                  16q21              up                                              0.891                                                1.740E-03                                            −0.185   −0.218   −0.853   −0.826

  4957             *ODF2*        outer dense fiber of sperm tails 2                                                                     9q34.11            up                                              0.854                                                1.185E-03                                            −0.232   −0.409   −0.610   −0.963

  57613            *KIAA1467*    KIAA1467                                                                                               12p13.1            up                                              0.837                                                4.169E-03                                            −0.382   −0.282   −0.398   −0.456

  7525             *YES1*        v-yes-1 Yamaguchi sarcoma viral oncogene homolog 1                                                     18p11.32           up                                              0.794                                                2.526E-03                                            −0.382   −0.447   −0.256   −0.446

  8751             *ADAM15*      ADAM metallopeptidase domain 15                                                                        1q22               up                                              0.787                                                6.433E-03                                            −0.233   −0.217   −0.383   −0.318

  7172             *TPMT*        thiopurine S-methyltransferase                                                                         6p22.3             up                                              0.786                                                1.524E-03                                            −0.167   −0.032   −0.482   −0.323

  4615             *MYD88*       myeloid differentiation primary response 88                                                            3p22.2             up                                              0.759                                                1.947E-03                                            −0.662   −0.118   −0.286   −0.113

  1678             *TIMM8A*      translocase of inner mitochondrial membrane 8 homolog A (yeast)                                        Xq22.1             up                                              0.729                                                2.723E-03                                            −0.530   −0.187   −0.201   −0.267

  3927             *LASP1*       LIM and SH3 protein 1                                                                                  17q12              up                                              0.692                                                2.348E-03                                            −0.280   −0.014   −0.319   −0.069

  10295            *BCKDK*       branched chain ketoacid dehydrogenase kinase                                                           16p11.2            up                                              0.685                                                6.186E-03                                            −0.281   −0.161   −0.439   −0.246

  26088            *GGA1*        golgi-associated, gamma adaptin ear containing, ARF binding protein 1                                  22q13.1            up                                              0.668                                                1.049E-03                                            −0.010   −0.074   −0.180   −0.202

  6240             *RRM1*        ribonucleotide reductase M1                                                                            11p15.4            up                                              0.667                                                4.582E-02                                            −0.206   −0.207   −1.158   −2.292

  219902           *TMEM136*     transmembrane protein 136                                                                              11q23.3            up                                              0.667                                                3.574E-03                                            −0.449   −0.477   −0.386   −0.405

  7019             *TFAM*        transcription factor A, mitochondrial                                                                  10q21.1            up                                              0.644                                                1.274E-02                                            −0.163   −0.413   −0.543   −0.609

  55775            *TDP1*        tyrosyl-DNA phosphodiesterase 1                                                                        14q32.11           up                                              0.624                                                1.316E-03                                            −0.151   −0.193   −0.651   −0.188

  79858            *NEK11*       NIMA-related kinase 11                                                                                 3q22.1             up                                              0.613                                                1.626E-03                                            −0.628   −0.563   −0.179   −0.189

  1889             *ECE1*        endothelin converting enzyme 1                                                                         1p36.12            up                                              0.604                                                3.635E-02                                            −0.949   −0.274   −0.559   −0.639

  65264            *UBE2Z*       ubiquitin-conjugating enzyme E2Z                                                                       17q21.32           up                                              0.590                                                1.348E-03                                            −0.352   −0.187   −0.895   −1.241

  9205             *ZMYM5*       zinc finger, MYM-type 5                                                                                13q12.11           up                                              0.582                                                7.805E-03                                            −0.413   −0.381   −0.699   −0.890

  996              *CDC27*       cell division cycle 27                                                                                 17q21.32           up                                              0.572                                                9.799E-03                                            −0.486   −0.018   −0.260   −0.099

  22898            *DENND3*      DENN/MADD domain containing 3                                                                          8q24.3             up                                              0.570                                                1.016E-02                                            −0.235   −0.012   −0.597   −0.926

  84314            *TMEM107*     transmembrane protein 107                                                                              17p13.1            up                                              0.570                                                2.965E-02                                            −0.471   −0.208   −0.199   −0.839

  85464            *SSH2*        slingshot protein phosphatase 2                                                                        17q11.2            up                                              0.562                                                2.440E-03                                            −0.296   −0.173   −0.433   −0.220

  56180            *MOSPD1*      motile sperm domain containing 1                                                                       Xq26.3             up                                              0.559                                                1.928E-02                                            −0.145   −0.237   −1.352   −1.270

  6625             *SNRNP70*     small nuclear ribonucleoprotein 70kDa (U1)                                                             19q13.33           up                                              0.554                                                1.725E-02                                            −0.373   −0.281   −0.663   −0.988

  60490            *PPCDC*       phosphopantothenoyl­-\                                                                                 15q24.2            up                                              0.550                                                1.182E-02                                            −0.269   −0.338   −0.057   −0.130
                                 cysteine decarboxylase                                                                                                                                                                                                                                                                                         

  147657           *ZNF480*      zinc finger protein 480                                                                                19q13.41           up                                              0.547                                                3.893E-02                                            −0.453   −0.035   −0.107   −0.047

  159090           *FAM122B*     family with sequence similarity 122B                                                                   Xq26.3             up                                              0.543                                                2.865E-02                                            −0.356   −0.131   −1.379   −1.493

  3150             *HMGN1*       high mobility group nucleosome binding\                                                                21q22.2            up                                              0.522                                                7.521E-03                                            −0.884   −0.157   −0.162   −0.119
                                 domain 1                                                                                                                                                                                                                                                                                                       

  7421             *VDR*         vitamin D (1,25-dihydroxyvitamin D3) receptor                                                          12q13.11           up                                              0.494                                                3.290E-02                                            −0.001   −0.069   −0.428   −0.417

  84705            *GTPBP3*      GTP binding protein 3 (mitochondrial)                                                                  19p13.11           up                                              0.485                                                1.999E-02                                            −0.156   −0.048   −0.488   −1.061

  84818            *IL17RC*      interleukin 17 receptor C                                                                              3p25.3             up                                              0.478                                                8.102E-03                                            −0.306   −0.009   −0.053   −0.194

  10102            *TSFM*        Ts translation elongation factor, mitochondrial                                                        12q14.1            up                                              0.475                                                4.873E-03                                            −0.170   −0.026   −0.951   −0.608

  27               *ABL2*        c-abl oncogene 2, non-receptor tyrosine kinase                                                         1q25.2             up                                              0.455                                                9.799E-03                                            −0.211   −0.281   −0.230   −0.102

  55285            *RBM41*       RNA binding motif\                                                                                     Xq22.3             up                                              0.415                                                1.538E-02                                            −0.055   −0.215   −0.495   −0.559
                                 protein 41                                                                                                                                                                                                                                                                                                     

  57532            *NUFIP2*      nuclear fragile X mental retardation protein interacting protein 2                                     17q11.2            up                                              0.397                                                1.056E-02                                            −0.098   −0.256   −0.425   −0.904

  84445            *LZTS2*       leucine zipper, putative tumor suppressor 2                                                            10q24.31           up                                              0.394                                                4.155E-02                                            −0.174   −0.125   −0.288   −0.026

  8243             *SMC1A*       structural maintenance of chromosomes 1A                                                               Xp11.22            up                                              0.390                                                3.635E-02                                            −0.163   −0.061   −0.917   −0.297

  54617            *INO80*       INO80 complex subunit                                                                                  15q15.1            up                                              0.384                                                2.835E-03                                            −0.594   −0.006   −0.635   −0.350

  7511             *XPNPEP1*     X-prolyl aminopeptidase (aminopeptidase P) 1, soluble                                                  10q25.1            up                                              0.381                                                7.521E-03                                            −0.648   −0.272   −1.595   −1.701

  23367            *LARP1*       La ribonucleoprotein domain family, member 1                                                           5q33.2             up                                              0.377                                                4.155E-02                                            −0.049   −0.003   −0.091   −0.216

  10146            *G3BP1*       GTPase activating protein (SH3 domain) binding protein 1                                               5q33.1             up                                              0.313                                                4.021E-02                                            −1.431   −0.040   −0.505   −0.475
  ------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

*UHRF1* was a direct target of *miR-145-5p* and *miR-145-3p* in BC cells {#s2_5}
------------------------------------------------------------------------

We performed quantitative real-time RT-PCR (qRT-PCR) to validate that *miR-145-5p* and *miR-145-3p* repressed *UHRF1* mRNA expression in BC cell lines, and we did indeed observe that it was significantly reduced in transfectants of these miRNAs in comparison with mock or miR-control transfectants (*P* \< 0.0001 and *P* = 0.0036, Figure [4A](#F4){ref-type="fig"}). The protein expression levels of UHRF1 were also repressed in the miRNAs transfectants (Figure [4B](#F4){ref-type="fig"}).

![Direct regulation of UHRF1 by *miR-145-5p* and *miR-145-3p*\
(**A**) *UHRF1* mRNA expression was evaluated by qRT-PCR in T24 and BOY 72 hours after transfection with *miR-145-5p* and *miR-145-3p*. *GUSB* was used as an internal control. \**P* = 0.0036 and \*\**P* \< 0.0001. (**B**) UHRF1 protein expression was evaluated by Western blot analyses in T24 and BOY 72--96 hours after transfection with *miR-145-5p* or *miR-145-3p*. GAPDH was used as a loading control. (**C**) *miR-145-5p* and *miR-145-3p* binding sites in the 3′ UTR of *UHRF1* mRNA. Dual Luciferase reporter assays using vectors encoding putative *miR-145-5p* and *miR-145-3p* target sites of the *UHRF* 3′ UTR (positions 1,179--1,198 and 287--292, respectively) for both wild-type and deleted regions. Normalized data were calculated as ratios of *Renilla*/firefly luciferase activities. \**P* \< 0.0001.](oncotarget-07-28460-g004){#F4}

We carried out dual luciferase reporter assays in T24 and BOY cells to determine whether the *UHRF1* gene was directly regulated by *miR-145-5p*/*3p*. The [microRNA.org](http://microrna.org/) database predicted that there was one binding site for *miR- 145-5p* in the 3′ UTR of *UHRF1* (position 1,179-- 1,198); for *miR-145-3p*, there was a binding site in the 3′ UTR at position 287--292. We used vectors encoding the partial wild-type sequence of the 3′ UTR of the mRNA, including the predicted *miR-145-5p* or *miR-145*- *3p* target sites. We found that the luminescence intensity was significantly reduced by co-transfection with these miRNAs and the vector carrying the wild-type 3′ UTR, whereas no reduction of luminescence was observed by transfection with the deletion vector (binding site had been removed) (*P* \< 0.0001, Figure [4C](#F4){ref-type="fig"}). These suggested that either of *miR-145-5p* and *miR-145-3p* were directly bounded to specific sites in the 3′ UTR of *UHRF1* mRNA.

Effects of silencing *UHRF1* in BC cell lines {#s2_6}
---------------------------------------------

To investigate the functional role of *UHRF1* in BC cells, we carried out loss-of-function studies by using *si-UHRF1* transfectants. First, we evaluated the knockdown efficiency of *si-UHRF1* transfection in BC cell lines. In the present study, we used two types of *si- UHRF1* (*si- UHRF1*-1 and *si-UHRF1*-2). The qRT- PCR and Western blot analyses showed that both siRNAs effectively downregulated UHRF1 expression in both cell lines (Figure [5A](#F5){ref-type="fig"} and [5B](#F5){ref-type="fig"}).

![*UHRF1* mRNA and protein expression after *si-UHRF1* transfection and effects of UHRF1 silencing in BC cell lines\
(**A**) *UHRF1* mRNA expression was evaluated by qRT-PCR in T24 and BOY 72 hours after transfection with *si-UHRF1*-1 and *si-UHRF1*-2. *GUSB* was used as an internal control. (**B**) UHRF1 protein expression was evaluated by Western blot analysis in T24 and BOY 72 - 96 hours after transfection with *miR-145-5p* or *miR-145-3p*. GAPDH was used as a loading control. (**C**) Cell proliferation was determined with the XTT assays 72 hours after transfection with 10 nM *si-UHRF1*-1 or *si-UHRF1*-2. \**P* \< 0.0001. (**D**) Cell migration activity was determined by wound-healing assays. \**P* \< 0.0001. (**E**) Cell invasion activity was determined using Matrigel invasion assays. \**P* \< 0.0001.](oncotarget-07-28460-g005){#F5}

XTT, cell migration, and invasion assays demonstrated that cell proliferation, cell migration, and cell invasion were inhibited in *si-UHRF1* transfectants in comparison with the mock or siRNA-control transfectant cells (each *P* \< 0.0001, Figure [5C](#F5){ref-type="fig"}, [5D](#F5){ref-type="fig"}, and [5E](#F5){ref-type="fig"}).

In the apoptosis assays, the apoptotic cell numbers were significantly greater in *si-UHRF1* transfectants than in mock or siRNA-control transfectants (Figure [6A](#F6){ref-type="fig"} and [6C](#F6){ref-type="fig"}). Western blot analyses showed that cleaved PARP expression was significantly increased in *si-UHRF1* transfectants compared with mock or siRNA-control transfectants (Figure [6B](#F6){ref-type="fig"} and [6D](#F6){ref-type="fig"}).

![Effects of silencing *UHRF1* on apoptosis in BC cell lines\
(**A**, **C**) Apoptosis assays were carried out using flow cytometry. Early apoptotic cells are in area R4 and apoptotic cells are in area R2. The normalized ratios of the apoptotic cells are shown in the histogram. Cycloheximide (2 μg/mL) was used as a positive control. \**P* \< 0.0001 (**B**, **D**) Western blot analyses for apoptotic markers (cleaved PARP) in BC cell lines. GAPDH was used as a loading control.](oncotarget-07-28460-g006){#F6}

Expression of *UHRF1* in BC clinical specimens {#s2_7}
----------------------------------------------

The qRT-PCR analyses showed that the expression level of *UHRF1* mRNA was significantly upregulated in 69 BC specimens and 2 BC cell lines compared with 12 NBE (*P* \< 0.0001, Figure [7A](#F7){ref-type="fig"}). Spearman\'s rank test showed negative correlations between *miR-145-5p*/*miR-145*-*3p* expression and *UHRF1* mRNA expression (*r* = −0.324 and −0.298, *P* = 0.0024 and 0.0051, Figure [7B](#F7){ref-type="fig"}). As shown in Figure [7C](#F7){ref-type="fig"}, the expression level of *UHRF1* was significantly greater in high grade clinical BCs (*P* = 0.0135), MIBCs (T2 ≤) (*P* = 0.0379), BCs with positive lymph node invasion (N1) (*P* = 0.00182), and in BCs with positive distant metastasis (M1) (*P* = 0.0307) than in their counterparts. Kaplan-Meier analysis showed that the high *UHRF1* expression group had significantly lower cause specific survival probabilities compared to the low *UHRF1* expression group (*P* = 0.0259, Figure [8](#F8){ref-type="fig"}).

![The expression level of *UHRF1* mRNA in BC clinical specimens and cell lines, and association of *UHRF1* expression with clinicopathological parameters\
(**A**) Expression levels of *UHRF1* in clinical specimens and BC cell lines were determined by qRT-PCR. Data were normalized to *GUSB* expression. (**B**) The correlated expression among *miR-145-5p*, *miR-145-3p*, and *UHRF1*. (**C**) Association of *UHRF1* expression with clinicopathological parameters. Relationships between two variables were analyzed using the Mann-Whitney *U* test.](oncotarget-07-28460-g007){#F7}

![The association between the expression level of *UHRF1* and cause specific survival rate\
Kaplan-Meier survival curves for cause specific survival rates based on *UHRF1* expression in 57 BC patients. *P*-values were calculated using the log-rank test.](oncotarget-07-28460-g008){#F8}

We validated the expression status of UHRF1 in BC clinical specimens using immunohistochemical staining. UHRF1 was expressed moderately or strongly in several cancer lesions, and normal bladder tissues stained weakly (Figure [9](#F9){ref-type="fig"}).

![Immunohistochemical staining of UHRF1 in BC clinical specimens\
UHRF1 was expressed more strongly in several cancer lesions than in noncancerous tissues. Left panel, original magnification ×40; Right panel, original magnification ×200. (**A**) Positively stained tumor lesion (High grade, T2bN0M0), (**B**) Positively stained tumor lesion (High grade, T1N0M0), (**C**) Positively stained tumor lesion (Low grade, T3N0M0), (**D**) Negative staining in normal bladder tissue.](oncotarget-07-28460-g009){#F9}

Investigation of downstream genes regulated by *UHRF1* in BC cells {#s2_8}
------------------------------------------------------------------

To identify the downstream genes regulated by *UHRF1*, genome-wide gene expression analyses and *in silico* analyses were performed in two BC cell lines transfected with *si-UHRF1*. A total of 533 genes were downregulated (log~2~ FC \< −1.5) by *si-UHRF1* transfection, and a total of 704 genes were upregulated (log~2~ FC \> 1.0) by *si-UHRF1* transfection compared with negative control cells (GEO, accession number: GSE77790). Among the downregulated genes in the *si-UHRF1* transfectants, 104 genes were upregulated in the BC clinical samples from GEO database (accession numbers: GSE11783, GSE31684), whereas among the upregulated genes, 62 genes were downregulated in the clinical BCs. These results imply that the 104 upregulated genes may act as oncogenes, and the 62 downregulated genes may act as tumor suppressors downstream from *UHRF1* in BC (Tables [2](#T2){ref-type="table"} and [3](#T3){ref-type="table"}).

###### Significantly downregulated genes by *si-UHRF1* in BC cell lines

  --------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  Entrez Gene ID   Gene Symbol   Description                                                            Genomic location   Gene Expression Omnibus\   Expression\                           
                                                                                                                           (GSE11783 + GSE31684)      in *si-UHRF1*\                        
                                                                                                                                                      transfectant\                         
                                                                                                                                                      (Log~2~ FC)                           
  ---------------- ------------- ---------------------------------------------------------------------- ------------------ -------------------------- ---------------- ----------- -------- --------
  7153             *TOP2A*       topoisomerase (DNA) II alpha 170kDa                                    17q21.2            up                         6.312            1.049E-03   −1.880   −1.681

  29128            *UHRF1*       ubiquitin-like with PHD and ring finger domains 1                      19p13.3            up                         4.984            1.049E-03   −3.213   −2.907

  259266           *ASPM*        asp (abnormal spindle) homolog, microcephaly associated (Drosophila)   1q31.3             up                         4.299            1.049E-03   −3.431   −3.444

  332              *BIRC5*       baculoviral IAP repeat containing 5                                    17q25.3            up                         4.110            1.049E-03   −2.258   −1.777

  9928             *KIF14*       kinesin family member 14                                               1q32.1             up                         3.866            1.049E-03   −3.294   −1.544

  1063             *CENPF*       centromere protein F, 350/400kDa                                       1q41               up                         3.576            1.049E-03   −2.613   −3.307

  1894             *ECT2*        epithelial cell transforming 2                                         3q26.31            up                         3.469            1.049E-03   −1.928   −1.813

  55247            *NEIL3*       nei endonuclease VIII-like 3 (E. coli)                                 4q34.3             up                         3.428            1.049E-03   −1.728   −2.065

  9401             *RECQL4*      RecQ protein-like 4                                                    8q24.3             up                         3.414            1.049E-03   −1.751   −2.102

  3832             *KIF11*       kinesin family member 11                                               10q23.33           up                         3.356            1.049E-03   −2.299   −1.657

  57082            *CASC5*       cancer susceptibility candidate 5                                      15q15.1            up                         3.230            1.049E-03   −2.470   −2.188

  151176           *FAM132B*     family with sequence similarity 132, member B                          2q37.3             up                         3.100            1.058E-03   −2.420   −2.184

  151246           *SGOL2*       shugoshin-like 2 (S. pombe)                                            2q33.1             up                         2.694            1.049E-03   −3.124   −2.407

  1062             *CENPE*       centromere protein E, 312kDa                                           4q24               up                         2.689            1.058E-03   −3.676   −3.218

  23529            *CLCF1*       cardiotrophin-like cytokine factor 1                                   11q13.2            up                         2.646            1.049E-03   −1.905   −2.363

  81930            *KIF18A*      kinesin family member 18A                                              11p14.1            up                         2.553            1.049E-03   −3.246   −2.128

  7130             *TNFAIP6*     tumor necrosis factor, alpha-induced protein 6                         2q23.3             up                         2.531            2.835E-03   −1.795   −2.735

  55502            *HES6*        hes family bHLH transcription factor 6                                 2q37.3             up                         2.506            6.688E-03   −1.572   −1.508

  5328             *PLAU*        plasminogen activator, urokinase                                       10q22.2            up                         2.244            1.740E-03   −2.417   −1.791

  9824             *ARHGAP11A*   Rho GTPase activating protein 11A                                      15q13.3            up                         2.051            2.348E-03   −1.675   −1.613

  23057            *NMNAT2*      nicotinamide nucleotide adenylyltransferase 2                          1q25.3             up                         2.050            1.247E-03   −1.707   −1.863

  59285            *CACNG6*      calcium channel, voltage-dependent, gamma subunit 6                    19q13.42           up                         2.016            1.049E-03   −1.502   −1.763

  675              *BRCA2*       breast cancer 2, early onset                                           13q13.1            up                         2.015            1.049E-03   −1.764   −2.356

  6524             *SLC5A2*      solute carrier family 5 (sodium/glucose cotransporter), member 2       16p11.2            up                         1.900            1.214E-03   −1.855   −1.569

  79412            *KREMEN2*     kringle containing transmembrane protein 2                             16p13.3            up                         1.893            1.348E-03   −2.309   −1.796

  6274             *S100A3*      S100 calcium binding protein A3                                        1q21.3             up                         1.825            8.102E-03   −2.215   −1.848

  5331             *PLCB3*       phospholipase C, beta 3 (phosphatidylinositol-specific)                11q13.1            up                         1.790            1.049E-03   −2.219   −1.735

  55349            *CHDH*        choline dehydrogenase                                                  3p21.1             up                         1.743            1.049E-03   −1.926   −2.008

  811              *CALR*        calreticulin                                                           19p13.2            up                         1.652            1.049E-03   −1.554   −1.500

  4987             *OPRL1*       opiate receptor-like 1                                                 20q13.33           up                         1.627            2.626E-03   −1.927   −1.766

  375248           *ANKRD36*     ankyrin repeat domain 36                                               2q11.2             up                         1.530            8.102E-03   −3.873   −1.791

  441054           *C4orf47*     chromosome 4 open reading frame 47                                     4q35.1             up                         1.485            2.151E-02   −2.229   −2.522

  201475           *RAB12*       RAB12, member RAS oncogene family                                      18p11.22           up                         1.468            1.058E-03   −2.353   −2.947

  286151           *FBXO43*      F-box protein 43                                                       8q22.2             up                         1.463            2.396E-02   −1.528   −2.082

  9091             *PIGQ*        phosphatidylinositol glycan anchor biosynthesis, class Q               16p13.3            up                         1.434            3.574E-03   −1.594   −1.693

  81575            *APOLD1*      apolipoprotein L domain containing 1                                   12p13.1            up                         1.354            1.808E-03   −2.237   −2.383

  132320           *SCLT1*       sodium channel and clathrin linker 1                                   4q28.2             up                         1.340            1.049E-03   −3.140   −3.098

  100131211        *TMEM194B*    transmembrane protein 194B                                             2q32.2             up                         1.325            1.049E-03   −1.573   −1.967

  153642           *ARSK*        arylsulfatase family, member K                                         5q15               up                         1.252            1.049E-03   −2.052   −1.875

  21               *ABCA3*       ATP-binding cassette, sub-family A (ABC1), member 3                    16p13.3            up                         1.170            4.892E-02   −1.879   −1.831

  55036            *CCDC40*      coiled-coil domain containing 40                                       17q25.3            up                         1.160            1.049E-03   −1.562   −1.531

  84259            *DCUN1D5*     DCN1, defective in cullin neddylation 1, domain containing 5           11q22.3            up                         1.151            1.247E-03   −1.591   −1.993

  80381            *CD276*       CD276 molecule                                                         15q24.1            up                         1.146            1.072E-03   −2.656   −2.096

  6487             *ST3GAL3*     ST3 beta-galactoside alpha-2,3-sialyltransferase 3                     1p34.1             up                         1.139            1.049E-03   −1.828   −2.380

  5351             *PLOD1*       procollagen-lysine, 2-oxoglutarate 5-dioxygenase 1                     1p36.22            up                         1.104            2.942E-03   −1.650   −1.570

  343099           *CCDC18*      coiled-coil domain containing 18                                       1p22.1             up                         1.075            1.578E-03   −3.521   −2.428

  30818            *KCNIP3*      Kv channel interacting protein 3, calsenilin                           2q11.1             up                         1.069            2.723E-03   −3.678   −2.733

  10051            *SMC4*        structural maintenance of chromosomes 4                                3q25.33            up                         1.066            1.578E-03   −2.612   −1.745

  51427            *ZNF107*      zinc finger protein 107                                                7q11.21            up                         1.040            1.316E-03   −2.527   −2.104

  10592            *SMC2*        structural maintenance of chromosomes 2                                9q31.1             up                         1.032            6.688E-03   −3.520   −2.180

  20               *ABCA2*       ATP-binding cassette, sub-family A (ABC1), member 2                    9q34.3             up                         0.965            1.372E-02   −1.511   −2.291

  55183            *RIF1*        replication timing regulatory factor 1                                 2q23.3             up                         0.960            1.058E-03   −1.712   −1.605

  9898             *UBAP2L*      ubiquitin associated protein 2-like                                    1q21.3             up                         0.952            1.049E-03   −1.587   −2.301

  29780            *PARVB*       parvin, beta                                                           22q13.31           up                         0.952            1.096E-02   −3.288   −1.888

  9585             *KIF20B*      kinesin family member 20B                                              10q23.31           up                         0.933            5.720E-03   −2.282   −3.122

  9534             *ZNF254*      zinc finger protein 254                                                19p12              up                         0.920            3.863E-03   −2.072   −2.662

  57520            *HECW2*       HECT, C2 and WW domain containing E3 ubiquitin protein ligase 2        2q32.3             up                         0.884            3.179E-03   −1.838   −1.958

  84083            *ZRANB3*      zinc finger, RAN-binding domain containing 3                           2q21.3             up                         0.873            1.578E-03   −1.987   −1.915

  6498             *SKIL*        SKI-like proto-oncogene                                                3q26.2             up                         0.859            1.808E-03   −2.709   −1.845

  64770            *CCDC14*      coiled-coil domain containing 14                                       3q21.1             up                         0.842            6.943E-03   −2.453   −1.711

  254065           *BRWD3*       bromodomain and WD repeat domain containing 3                          Xq21.1             up                         0.808            1.393E-03   −1.852   −2.546

  22973            *LAMB2P1*     laminin, beta 2 pseudogene 1                                           3p21.31            up                         0.804            7.521E-03   −2.336   −2.311

  7525             *YES1*        YES proto-oncogene 1, Src family tyrosine kinase                       18p11.32           up                         0.794            2.526E-03   −3.127   −2.099

  1984             *EIF5A*       eukaryotic translation initiation factor 5A                            17p13.1            up                         0.793            5.486E-03   −2.297   −2.018

  22852            *ANKRD26*     ankyrin repeat domain 26                                               10p12.1            up                         0.787            3.303E-03   −2.798   −2.663

  23322            *RPGRIP1L*    RPGRIP1-like                                                           16q12.2            up                         0.778            1.182E-02   −1.517   −1.806

  79677            *SMC6*        structural maintenance of chromosomes 6                                2p24.2             up                         0.764            8.401E-03   −1.909   −2.083

  84920            *ALG10*       ALG10, alpha-1,2-glucosyltransferase                                   12p11.1            up                         0.763            6.688E-03   −1.828   −2.360

  8570             *KHSRP*       KH-type splicing regulatory protein                                    19p13.3            up                         0.762            3.303E-03   −1.767   −1.820

  5819             *PVRL2*       poliovirus receptor-related 2 (herpesvirus entry mediator B)           19q13.32           up                         0.757            9.078E-03   −3.014   −2.465

  51575            *ESF1*        ESF1, nucleolar pre-rRNA processing protein, homolog (S. cerevisiae)   20p12.1            up                         0.755            9.430E-03   −1.786   −1.732

  51361            *HOOK1*       hook microtubule-tethering protein 1                                   1p32.1             up                         0.689            3.067E-02   −2.156   −2.000

  10198            *MPHOSPH9*    M-phase phosphoprotein 9                                               12q24.31           up                         0.667            1.947E-03   −2.113   −1.502

  4983             *OPHN1*       oligophrenin 1                                                         Xq12               up                         0.632            5.277E-03   −2.278   −1.747

  4976             *OPA1*        optic atrophy 1 (autosomal dominant)                                   3q29               up                         0.619            2.169E-03   −2.190   −1.526

  168850           *ZNF800*      zinc finger protein 800                                                7q31.33            up                         0.611            1.227E-02   −1.807   −1.867

  26272            *FBXO4*       F-box protein 4                                                        5p13.1             up                         0.611            3.512E-02   −2.224   −2.445

  7390             *UROS*        uroporphyrinogen III synthase                                          10q26.13           up                         0.605            6.433E-03   −3.120   −2.062

  4683             *NBN*         nibrin                                                                 8q21.3             up                         0.590            5.720E-03   −2.986   −1.966

  79670            *ZCCHC6*      zinc finger, CCHC domain containing 6                                  9q21.33            up                         0.587            5.486E-03   −2.353   −1.839

  79573            *TTC13*       tetratricopeptide repeat domain 13                                     1q42.2             up                         0.587            6.943E-03   −1.740   −2.064

  50840            *TAS2R14*     taste receptor, type 2, member 14                                      12p13.2            up                         0.574            1.598E-02   −1.947   −1.509

  79042            *TSEN34*      TSEN34 tRNA splicing endonuclease subunit                              19q13.42           up                         0.570            1.138E-02   −2.455   −1.761

  6801             *STRN*        striatin, calmodulin binding protein                                   2p22.2             up                         0.563            2.723E-03   −1.964   −2.434

  3597             *IL13RA1*     interleukin 13 receptor, alpha 1                                       Xq24               up                         0.552            2.075E-02   −2.460   −2.403

  147657           *ZNF480*      zinc finger protein 480                                                19q13.41           up                         0.547            3.893E-02   −3.434   −3.276

  8683             *SRSF9*       serine/arginine-rich splicing factor 9                                 12q24.31           up                         0.534            1.227E-02   −1.523   −2.098

  252983           *STXBP4*      syntaxin binding protein 4                                             17q22              up                         0.516            2.151E-02   −1.776   −1.599

  284325           *C19orf54*    chromosome 19 open reading frame 54                                    19q13.2            up                         0.510            4.734E-02   −1.614   −2.171

  91147            *TMEM67*      transmembrane protein 67                                               8q22.1             up                         0.509            9.799E-03   −1.647   −2.069

  114799           *ESCO1*       establishment of sister chromatid cohesion N-acetyltransferase 1       18q11.2            up                         0.495            4.873E-03   −2.173   −2.401

  57670            *KIAA1549*    KIAA1549                                                               7q34               up                         0.480            4.582E-02   −2.127   −1.789

  6103             *RPGR*        retinitis pigmentosa GTPase regulator                                  Xp11.4             up                         0.467            3.290E-02   −1.583   −2.025

  5700             *PSMC1*       proteasome (prosome, macropain) 26S subunit, ATPase, 1                 14q32.11           up                         0.449            1.274E-02   −1.639   −1.711

  253260           *RICTOR*      RPTOR independent companion of MTOR, complex 2                         5p13.1             up                         0.442            2.666E-02   −2.458   −1.683

  23241            *PACS2*       phosphofurin acidic cluster sorting protein 2                          14q32.33           up                         0.442            3.179E-03   −3.416   −2.028

  27154            *BRPF3*       bromodomain and PHD finger containing, 3                               6p21.31            up                         0.440            5.720E-03   −1.772   −2.598

  7703             *PCGF2*       polycomb group ring finger 2                                           17q12              up                         0.439            2.865E-02   −1.828   −1.974

  51105            *PHF20L1*     PHD finger protein 20-like 1                                           8q24.22            up                         0.383            9.078E-03   −3.492   −2.007

  57697            *FANCM*       Fanconi anemia, complementation group M                                14q21.2            up                         0.364            3.067E-02   −1.648   −1.627

  9730             *VPRBP*       Vpr (HIV-1) binding protein                                            3p21.2             up                         0.363            2.075E-02   −2.342   −1.568

  5378             *PMS1*        PMS1 postmeiotic segregation increased 1 (S. cerevisiae)               2q32.2             up                         0.350            4.734E-02   −2.701   −1.616

  255520           *ELMOD2*      ELMO/CED-12 domain containing 2                                        4q31.1             up                         0.334            4.582E-02   −2.360   −1.637

  80124            *VCPIP1*      valosin containing protein (p97)/p47 complex interacting protein 1     8q13.1             up                         0.304            3.893E-02   −3.107   −2.286
  --------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

###### Significantly upregulated genes by *si-UHRF1* in BC cell lines

  ------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  Entrez Gene ID   Gene Symbol    Description                                                                                                     Genomic location   Gene Expression Omnibus\   Expression\                          
                                                                                                                                                                     (GSE11783 + GSE31684)      in *si-UHRF1*\                       
                                                                                                                                                                                                transfectant\                        
                                                                                                                                                                                                (Log~2~ FC)                          
  ---------------- -------------- --------------------------------------------------------------------------------------------------------------- ------------------ -------------------------- ---------------- ----------- ------- -------
  3043             *HBB*          hemoglobin, beta                                                                                                11p15.4            down                       −3.263           1.214E-03   1.204   2.109

  137835           *TMEM71*       transmembrane protein 71                                                                                        8q24.22            down                       −2.428           4.873E-03   2.813   3.920

  8639             *AOC3*         amine oxidase, copper containing 3                                                                              17q21.31           down                       −2.188           1.434E-03   1.907   3.140

  1408             *CRY2*         cryptochrome circadian clock 2                                                                                  11p11.2            down                       −2.141           1.058E-03   2.134   2.108

  7644             *ZNF91*        zinc finger protein 91                                                                                          19p12              down                       −2.058           1.155E-03   1.435   2.063

  197257           *LDHD*         lactate dehydrogenase D                                                                                         16q23.1            down                       −1.626           2.965E-02   1.844   1.362

  316              *AOX1*         aldehyde oxidase 1                                                                                              2q33.1             down                       −1.601           2.169E-03   1.841   1.049

  26051            *PPP1R16B*     protein phosphatase 1, regulatory subunit 16B                                                                   20q11.23           down                       −1.547           6.688E-03   1.076   1.198

  63976            *PRDM16*       PR domain containing 16                                                                                         1p36.32            down                       −1.439           2.075E-02   2.639   3.846

  254827           *NAALADL2*     N-acetylated alpha-linked acidic dipeptidase-like 2                                                             3q26.31            down                       −1.313           4.873E-03   1.621   3.168

  154              *ADRB2*        adrenoceptor beta 2, surface                                                                                    5q32               down                       −1.242           9.799E-03   2.384   2.302

  10477            *UBE2E3*       ubiquitin-conjugating enzyme E2E 3                                                                              2q31.3             down                       −1.117           1.135E-03   1.053   2.755

  7099             *TLR4*         toll-like receptor 4                                                                                            9q33.1             down                       −1.053           6.943E-03   1.402   2.356

  57478            *USP31*        ubiquitin specific peptidase 31                                                                                 16p12.2            down                       −1.037           4.169E-03   1.570   1.234

  57185            *NIPAL3*       NIPA-like domain containing 3                                                                                   1p36.11            down                       −0.986           1.316E-03   1.329   1.189

  30815            *ST6GALNAC6*   ST6 (alpha-N-acetyl-neuraminyl-2,3-beta-galactosyl-1,3)-N-acetylgalactosaminide alpha-2,6-sialyltransferase 6   9q34.11            down                       −0.936           1.660E-02   1.093   2.348

  29915            *HCFC2*        host cell factor C2                                                                                             12q23.3            down                       −0.928           1.393E-03   1.304   1.296

  54741            *LEPROT*       leptin receptor overlapping transcript                                                                          1p31.3             down                       −0.893           1.049E-03   1.280   2.248

  7779             *SLC30A1*      solute carrier family 30 (zinc transporter), member 1                                                           1q32.3             down                       −0.879           8.736E-03   1.267   1.262

  79027            *ZNF655*       zinc finger protein 655                                                                                         7q22.1             down                       −0.863           1.393E-03   1.570   1.589

  64344            *HIF3A*        hypoxia inducible factor 3, alpha subunit                                                                       19q13.32           down                       −0.845           1.016E-02   1.284   2.411

  79844            *ZDHHC11*      zinc finger, DHHC-type containing 11                                                                            5p15.33            down                       −0.834           3.176E-02   1.505   1.890

  79815            *NIPAL2*       NIPA-like domain containing 2                                                                                   8q22.2             down                       −0.825           6.688E-03   1.929   1.259

  7923             *HSD17B8*      hydroxysteroid (17-beta) dehydrogenase 8                                                                        6p21.32            down                       −0.821           3.512E-02   2.657   3.759

  8629             *JRK*          Jrk homolog (mouse)                                                                                             8q24.3             down                       −0.820           1.740E-03   1.358   2.076

  79591            *C10orf76*     chromosome 10 open reading frame 76                                                                             10q24.32           down                       −0.812           1.808E-03   1.099   1.917

  599              *BCL2L2*       BCL2-like 2                                                                                                     14q11.2            down                       −0.775           2.835E-03   1.384   1.730

  412              *STS*          steroid sulfatase (microsomal), isozyme S                                                                       Xp22.31            down                       −0.770           1.372E-02   1.440   1.471

  56900            *TMEM167B*     transmembrane protein 167B                                                                                      1p13.3             down                       −0.755           2.626E-03   2.282   2.366

  23509            *POFUT1*       protein O-fucosyltransferase 1                                                                                  20q11.21           down                       −0.747           1.274E-02   1.400   2.132

  25923            *ATL3*         atlastin GTPase 3                                                                                               11q12.3            down                       −0.727           3.290E-02   1.179   1.907

  79669            *C3orf52*      chromosome 3 open reading frame 52                                                                              3q13.2             down                       −0.708           4.021E-02   1.200   1.482

  55844            *PPP2R2D*      protein phosphatase 2, regulatory subunit B, delta                                                              10q26.3            down                       −0.691           2.666E-02   1.422   1.303

  5939             *RBMS2*        RNA binding motif, single stranded interacting protein 2                                                        12q13.3            down                       −0.626           5.943E-03   1.193   1.438

  6158             *RPL28*        ribosomal protein L28                                                                                           19q13.42           down                       −0.618           1.808E-03   2.026   3.427

  2145             *EZH1*         enhancer of zeste 1 polycomb repressive complex 2 subunit                                                       17q21.2            down                       −0.618           1.393E-03   1.391   1.171

  388969           *C2orf68*      chromosome 2 open reading frame 68                                                                              2p11.2             down                       −0.611           3.435E-03   1.309   1.192

  55422            *ZNF331*       zinc finger protein 331                                                                                         19q13.42           down                       −0.594           1.725E-02   2.855   2.230

  92400            *RBM18*        RNA binding motif protein 18                                                                                    9q33.2             down                       −0.594           8.401E-03   1.172   2.001

  80017            *C14orf159*    chromosome 14 open reading frame 159                                                                            14q32.11           down                       −0.590           1.182E-02   1.072   1.748

  7556             *ZNF10*        zinc finger protein 10                                                                                          12q24.33           down                       −0.563           1.480E-02   1.592   1.127

  55957            *LIN37*        lin-37 DREAM MuvB core complex component                                                                        19q13.12           down                       −0.543           1.857E-02   1.002   1.205

  84267            *C9orf64*      chromosome 9 open reading frame 64                                                                              9q21.32            down                       −0.543           5.720E-03   1.215   1.299

  8799             *PEX11B*       peroxisomal biogenesis factor 11 beta                                                                           1q21.1             down                       −0.535           4.679E-03   1.083   1.163

  8790             *FPGT*         fucose-1-phosphate guanylyltransferase                                                                          1p31.1             down                       −0.524           2.075E-02   1.680   1.222

  6992             *PPP1R11*      protein phosphatase 1, regulatory (inhibitor) subunit 11                                                        6p22.1             down                       −0.517           6.433E-03   1.104   1.329

  116224           *FAM122A*      family with sequence similarity 122A                                                                            9q21.11            down                       −0.507           2.169E-03   1.231   1.549

  51710            *ZNF44*        zinc finger protein 44                                                                                          19p13.2            down                       −0.499           1.372E-02   2.385   1.001

  7265             *TTC1*         tetratricopeptide repeat domain 1                                                                               5q33.3             down                       −0.487           1.182E-02   1.109   1.112

  80213            *TM2D3*        TM2 domain containing 3                                                                                         15q26.3            down                       −0.485           1.182E-02   1.342   1.742

  81631            *MAP1LC3B*     microtubule-associated protein 1 light chain 3 beta                                                             16q24.2            down                       −0.480           1.725E-02   1.210   2.109

  6016             *RIT1*         Ras-like without CAAX 1                                                                                         1q22               down                       −0.473           2.666E-02   1.556   1.432

  7247             *TSN*          translin                                                                                                        2q14.3             down                       −0.467           4.582E-02   1.101   1.496

  167227           *DCP2*         decapping mRNA 2                                                                                                5q22.2             down                       −0.447           1.016E-02   1.284   1.104

  11046            *SLC35D2*      solute carrier family 35 (UDP-GlcNAc/UDP-glucose transporter), member D2                                        9q22.32            down                       −0.431           1.227E-02   1.318   1.340

  54946            *SLC41A3*      solute carrier family 41, member 3                                                                              3q21.2             down                       −0.402           4.294E-02   1.526   1.988

  7799             *PRDM2*        PR domain containing 2, with ZNF domain                                                                         1p36.21            down                       −0.384           7.805E-03   1.438   1.294

  6651             *SON*          SON DNA binding protein                                                                                         21q22.11           down                       −0.374           5.486E-03   1.126   1.155

  80255            *SLC35F5*      solute carrier family 35, member F5                                                                             2q14.1             down                       −0.369           4.441E-02   1.143   1.619

  55197            *RPRD1A*       regulation of nuclear pre-mRNA domain containing 1A                                                             18q12.2            down                       −0.364           3.893E-02   1.480   1.761

  91603            *ZNF830*       zinc finger protein 830                                                                                         17q12              down                       −0.358           2.075E-02   1.040   1.085

  5094             *PCBP2*        poly(rC) binding protein 2                                                                                      12q13.13           down                       −0.286           4.734E-02   1.454   1.158
  ------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

To further investigate the *UHRF1* downstream genes, we performed the classification of these candidate genes to known molecular pathways by using DAVID program (<https://david.ncifcrf.gov/>). Classification strategy of downstream genes by *si-UHRF1* transfectants is shown in Figure [10A](#F10){ref-type="fig"} and [10B](#F10){ref-type="fig"}. Significantly upregulated and downregulated pathways and their involved genes are indicated in Tables [4](#T4){ref-type="table"} and [5](#T5){ref-type="table"}. Several genes were classified into biological process categories and a variety of biological pathways, "M phase", "cell cycle", and "cell cycle phase" were significantly downregulated by *si- UHRF1* transfectants (Table [4](#T4){ref-type="table"}).

![Flow chart demonstrating the strategy for analysis of genes regulated by *UHRF1*\
(**A**) A total of 2,222 and 1,512 downregulated genes in expression analyses of *si-UHRF1* transfectants of BC cell lines (T24 and BOY, respectively) were selected. We then analyzed 533 common downregulated genes by using available GEO data sets (GSE11783 + GSE31684). The analyses showed that 104 genes were significantly upregulated in BC specimens compared with NBE. (**B**) A total of 2,665 and 2,434 upregulated genes in expression analysis of *si-UHRF1* transfectants of BC cell lines (T24 and BOY, respectively) were selected. We then analyzed 704 common upregulated genes by using GEO data sets. The analyses showed that 62 genes were significantly downregulated in BC specimens compared with NBE.](oncotarget-07-28460-g010){#F10}

###### Downregulated genes by *si-UHRF1* were classified by DAVID program

  Biological process                                                                             Number of genes   *P*-Value   Genes
  ---------------------------------------------------------------------------------------------- ----------------- ----------- ----------------------------------------------------------------------------------------------------------------------------------------------
  M phase                                                                                        15                8.10E-09    *ASPM, BIRC5, BRCA2, CENPE, CENPF, FBXO43, KIF11, KIF18A, KIF20B, MPHOSPH9, NBN, SGOL2, SMC2, SMC4, VCPIP1*
  cell cycle                                                                                     20                1.10E-07    *ASPM, BIRC5, BRCA2, CALR, CENPE, CENPF, ESCO1, FBXO43, KIF11, KIF18A, KIF20B, MPHOSPH9, NBN, PSMC1, RIF1, SGOL2, SMC2, SMC4, UHRF1, VCPIP1*
  cell cycle phase                                                                               15                1.40E-07    *ASPM, BIRC5, BRCA2, CENPE, CENPF, FBXO43, KIF11, KIF18A, KIF20B, MPHOSPH9, NBN, SGOL2, SMC2, SMC4, VCPIP1*
  cell cycle process                                                                             17                1.90E-07    *ASPM, BIRC5, BRCA2, CALR, CENPE, CENPF, FBXO43, KIF11, KIF18A, KIF20B, MPHOSPH9, NBN, PSMC1, SGOL2, SMC2, SMC4, VCPIP1*
  chromosome segregation                                                                         8                 5.20E-07    *BIRC5, CENPE, CENPF, KIF18A, SGOL2, SMC2, SMC4, TOP2A*
  M phase of mitotic cell cycle                                                                  11                8.50E-07    *ASPM, BIRC5, CENPE, CENPF, KIF11, KIF18A, KIF20B, MPHOSPH9, SMC2, SMC4, VCPIP1*
  organelle fission                                                                              11                1.00E-06    *ASPM, BIRC5, CENPE, CENPF, KIF11, KIF18A, KIF20B, OPA1, SMC2, SMC4, VCPIP1*
  mitosis                                                                                        10                6.40E-06    *ASPM, BIRC5, CENPE, CENPF, KIF11, KIF18A, KIF20B, SMC2, SMC4, VCPIP1*
  nuclear division                                                                               10                6.40E-06    *ASPM, BIRC5, CENPE, CENPF, KIF11, KIF18A, KIF20B, SMC2, SMC4, VCPIP1*
  mitotic cell cycle                                                                             12                1.20E-05    *ASPM, BIRC5, CENPE, CENPF, KIF11, KIF18A, KIF20B, MPHOSPH9, PSMC1, SMC2, SMC4, VCPIP1*
  DNA repair                                                                                     10                4.90E-05    *BRCA2, ESCO1, FANCM, NBN, NEIL3, PMS1, RECQL4, SMC6, TOP2A, UHRF1*
  cell division                                                                                  10                6.50E-05    *ASPM, BIRC5, BRCA2, CENPE, CENPF, KIF11, KIF20B, SGOL2, SMC2, SMC4*
  response to DNA damage stimulus                                                                11                7.40E-05    *BRCA2, ESCO1, FANCM, NBN, NEIL3, PMS1, RECQL4, RIF1, SMC6, TOP2A, UHRF1*
  establishment of chromosome localization                                                       4                 8.90E-05    *BIRC5, CENPE, CENPF, KIF18A*
  chromosome localization                                                                        4                 8.90E-05    *BIRC5, CENPE, CENPF, KIF18A*
  chromosome organization                                                                        12                1.40E-04    *BRCA2, BRPF3, CENPE, CENPF, FBXO4, KIF18A, NBN, PCGF2, SGOL2, SMC2, SMC4, TOP2A*
  DNA metabolic process                                                                          12                2.00E-04    *BRCA2, CENPF, ESCO1, FANCM, FBXO4, NBN, NEIL3, PMS1, RECQL4, SMC6, TOP2A, UHRF1*
  microtubule-based movement                                                                     6                 5.80E-04    *CENPE, KIF11, KIF14, KIF18A, KIF20B, OPA1*
  regulation of cell cycle process                                                               6                 6.00E-04    *BIRC5, BRCA2, CALR, CENPE, CENPF, KIF20B*
  microtubule-based process                                                                      8                 7.90E-04    *BRCA2, CENPE, HOOK1, KIF11, KIF14, KIF18A, KIF20B, OPA1*
  mitotic sister chromatid segregation                                                           4                 1.30E-03    *CENPE, KIF18A, SMC2, SMC4*
  sister chromatid segregation                                                                   4                 1.40E-03    *CENPE, KIF18A, SMC2, SMC4*
  metaphase plate congression                                                                    3                 1.90E-03    *CENPE, CENPF, KIF18A*
  cellular response to stress                                                                    11                2.00E-03    *BRCA2, ESCO1, FANCM, NBN, NEIL3, PMS1, RECQL4, RIF1, SMC6, TOP2A, UHRF1*
  regulation of mitotic cell cycle                                                               6                 2.20E-03    *BIRC5, BRCA2, CENPE, CENPF, KIF20B, NBN*
  organelle localization                                                                         5                 2.20E-03    *ASPM, BIRC5, CENPE, CENPF, KIF18A*
  spindle checkpoint                                                                             3                 2.20E-03    *BIRC5, CENPE, CENPF*
  positive regulation of cell cycle                                                              4                 4.80E-03    *BIRC5, BRCA2, CALR, CENPE*
  establishment of organelle localization                                                        4                 8.20E-03    *BIRC5, CENPE, CENPF, KIF18A*
  chromosome condensation                                                                        3                 9.70E-03    *SMC2, SMC4, TOP2A*
  glucose transport                                                                              3                 1.30E-02    *SLC5A2, STXBP4, YES1*
  hexose transport                                                                               3                 1.40E-02    *SLC5A2, STXBP4, YES1*
  regulation of cell cycle                                                                       7                 1.40E-02    *BIRC5, BRCA2, CALR, CENPE, CENPF, KIF20B, NBN*
  monosaccharide transport                                                                       3                 1.50E-02    *SLC5A2, STXBP4, YES1*
  negative regulation of neuron differentiation                                                  3                 1.70E-02    *ASPM, CALR, NBN*
  cell cycle checkpoint                                                                          4                 1.70E-02    *BIRC5, CENPE, CENPF, NBN*
  kinetochore assembly                                                                           2                 1.80E-02    *CENPE, CENPF*
  meiosis                                                                                        4                 2.10E-02    *BRCA2, FBXO43, NBN, SGOL2*
  M phase of meiotic cell cycle                                                                  4                 2.10E-02    *BRCA2, FBXO43, NBN, SGOL2*
  meiotic cell cycle                                                                             4                 2.20E-02    *BRCA2, FBXO43, NBN, SGOL2*
  germ cell development                                                                          4                 2.30E-02    *BRCA2, CASC5, HOOK1, PVRL2*
  kinetochore organization                                                                       2                 2.40E-02    *CENPE, CENPF*
  DNA recombination                                                                              4                 2.50E-02    *BRCA2, NBN, RECQL4, SMC6*
  mitotic cell cycle checkpoint                                                                  3                 2.70E-02    *CENPE, CENPF, NBN*
  centromere complex assembly                                                                    2                 3.50E-02    *CENPE, CENPF*
  spermatid development                                                                          3                 4.10E-02    *CASC5, HOOK1, PVRL2*
  regulation of nuclear division                                                                 3                 4.40E-02    *CENPE, CENPF, KIF20B*
  regulation of mitosis                                                                          3                 4.40E-02    *CENPE, CENPF, KIF20B*
  negative regulation of macromolecule biosynthetic process                                      8                 4.50E-02    *BRCA2, CALR, CD276, CENPF, KCNIP3, PCGF2, SKIL, ZNF254*
  spermatid differentiation                                                                      3                 4.60E-02    *CASC5, HOOK1, PVRL2*
  cytoskeleton organization                                                                      7                 4.60E-02    *BRCA2, CALR, HOOK1, KIF11, KIF18A, OPHN1, RICTOR*
  negative regulation of cellular biosynthetic process                                           8                 5.10E-02    *BRCA2, CALR, CD276, CENPF, KCNIP3, PCGF2, SKIL, ZNF254*
  positive regulation of cellular protein metabolic process                                      5                 5.10E-02    *CLCF1, EIF5A, FBXO4, PSMC1, RICTOR*
  carbohydrate transport                                                                         3                 5.20E-02    *SLC5A2, STXBP4, YES1*
  mitotic metaphase plate congression                                                            2                 5.30E-02    *CENPE, KIF18A*
  regulation of DNA replication                                                                  3                 5.30E-02    *BRCA2, CALR, NBN*
  double-strand break repair                                                                     3                 5.30E-02    *BRCA2, NBN, RECQL4*
  negative regulation of biosynthetic process                                                    8                 5.50E-02    *BRCA2, CALR, CD276, CENPF, KCNIP3, PCGF2, SKIL, ZNF254*
  positive regulation of protein metabolic process                                               5                 5.80E-02    *CLCF1, EIF5A, FBXO4, PSMC1, RICTOR*
  microtubule cytoskeleton organization                                                          4                 5.80E-02    *BRCA2, HOOK1, KIF11, KIF18A*
  negative regulation of mitotic metaphase/anaphase transition                                   2                 6.40E-02    *CENPE, CENPF*
  blastocyst growth                                                                              2                 6.40E-02    *BRCA2, NBN*
  mitotic cell cycle spindle assembly checkpoint                                                 2                 6.40E-02    *CENPE, CENPF*
  positive regulation of mitotic cell cycle                                                      2                 7.00E-02    *BIRC5, BRCA2*
  negative regulation of mitosis                                                                 2                 7.00E-02    *CENPE, CENPF*
  negative regulation of nuclear division                                                        2                 7.00E-02    *CENPE, CENPF*
  negative regulation of macromolecule metabolic process                                         9                 7.20E-02    *BRCA2, CALR, CD276, CENPF, KCNIP3, PCGF2, PSMC1, SKIL, ZNF254*
  reproductive cellular process                                                                  4                 7.30E-02    *BRCA2, CASC5, HOOK1, PVRL2*
  mitotic chromosome condensation                                                                2                 7.50E-02    *SMC2, SMC4*
  negative regulation of transcription from RNA polymerase II promoter                           5                 7.50E-02    *CALR, KCNIP3, PCGF2, SKIL, ZNF254*
  protein localization                                                                           10                8.00E-02    *CALR, CENPE, CENPF, EIF5A, HOOK1, KIF18A, RAB12, RPGR, SGOL2, STXBP4*
  negative regulation of nucleobase, nucleoside, nucleotide and nucleic acid metabolic process   7                 8.60E-02    *BRCA2, CALR, CENPF, KCNIP3, PCGF2, SKIL, ZNF254*
  establishment of protein localization                                                          9                 8.90E-02    *CALR, CENPE, CENPF, EIF5A, HOOK1, KIF18A, RAB12, RPGR, STXBP4*
  in utero embryonic development                                                                 4                 8.90E-02    *BRCA2, NBN, PCGF2, RPGRIP1L*
  negative regulation of nitrogen compound metabolic process                                     7                 9.10E-02    *BRCA2, CALR, CENPF, KCNIP3, PCGF2, SKIL, ZNF254*
  positive regulation of cellular component organization                                         4                 9.50E-02    *CALR, CENPE, EIF5A, RICTOR*
  developmental growth                                                                           3                 9.60E-02    *BRCA2, NBN, PLAU*

###### Upregulated genes by *si-UHRF1* were classified by DAVID program

  Biological process                                         Number of genes   *P*-Value   Genes
  ---------------------------------------------------------- ----------------- ----------- ----------------------------------------------------------------------------------------------------------
  regulation of transcription                                15                1.40E-02    *CRY2, ADRB2, EZH1, HCFC2, HIF3A, JRK, POFUT1, PRDM16, PRDM2, TLR4, ZNF10, ZNF331, ZNF44, ZNF655, ZNF91*
  regulation of transcription, DNA-dependent                 10                7.00E-02    *ADRB2, HCFC2, HIF3A, PRDM16, PRDM2, ZNF10, ZNF331, ZNF44, ZNF655, ZNF91*
  regulation of RNA metabolic process                        10                7.90E-02    *ADRB2, HCFC2, HIF3A, PRDM16, PRDM2, ZNF10, ZNF331, ZNF44, ZNF655, ZNF91*
  negative regulation of myeloid leukocyte differentiation   2                 4.90E-02    *PRDM16, TLR4*
  fucose metabolic process                                   2                 5.20E-02    *POFUT1, FPGT*
  brown fat cell differentiation                             2                 6.90E-02    *ADRB2, PRDM16*
  negative regulation of myeloid cell differentiation        2                 8.50E-02    *PRDM16, TLR4*

DISCUSSION {#s3}
==========

miRNAs are critical regulators of gene expression and they control many physiologic processes in mammalian cells \[[@R5]--[@R7]\]. There are abundant evidences that aberrantly expressed miRNAs can dysregulate otherwise well-controlled cellular RNA networks, thereby enhancing cancer cell development, progression, and metastasis \[[@R6]--[@R9]\]. The discovery of aberrantly expressed miRNAs and the resultant changes in RNA networks in cancer cells provide novel molecular explanations for cancer cell progression and metastasis. It is now apparent that dysregulated miRNAs play important roles in BC cell development \[[@R16]\]. Our past miRNA studies of BC cells showed that clustered miRNAs (including *miR-1*/*133a* (targeting *TAGLN2*), *miR-23b*/*27b*/*24-1* (targeting *EGFR*, *MET*, and *FOXM1*), and *miR-195*/*497* (targeting *BIRC5* and *WNT7A*)) act as tumor-suppressive miRNAs through their regulation of several oncogenic genes and pathways \[[@R10], [@R17]--[@R19]\].

Improved technological developments (next generation sequencing) have illuminated the role of miRNA networks in cancer cells. In this study, we examined the expression of *miR-145-5p* and *miR-145 3p* in BC cells because these miRNAs were significantly reduced in cancer cells as determined by deep sequencing. Our data demonstrated that *miR-145-3p* (the passenger-strand from *pre-miR-145*) had anti-tumor effects through targeting of *UHRF1* in BC cells.

Downregulation of *miR-145-5p* (the guide-strand) is frequently observed in many types of cancer, and past studies have established the anti-tumor function of *miR-145-5p* through its regulation of several types of oncogenes in cancer cells \[[@R15]\]. Our group also identified the anti-tumor function of *miR-145-5p* in prostate cancer, renal cell carcinoma, bladder cancer, and esophageal squamous cell carcinoma \[[@R20]--[@R23]\]. Importantly, *p53* appears to transcriptionally regulate *miR-145-5p* by interaction with a potential *p53* response element at the *pre-miR-145* promoter region \[[@R24]\]. Moreover, *c-MYC* is directly repressed by *miR-145-5p*, indicating that it acts as a new member of the *p53* regulatory network and contributes to the direct linkage between *p53* and *c-MYC* in human cancer pathways \[[@R24]\]. In contrast to *miR-145-5p*, the functional significance of *miR-145-3p* in cancer cells has been obscure. This is the first report to evaluate the anti-tumor function of *miR-145-3p* in BC cells by gain-of-function assays.

miRNAs are often associated in clusters in the genome, and several studies have focused on the functional role of clustered miRNAs in human cancers \[[@R17], [@R18], [@R20]--[@R23], [@R25]\]. In the human genome, 429 human miRNAs have been found to be clustered at 144 sites, with inter-miRNA distances of less than 5,000 base pair (miRBase, release 21). Both *miR-143* and *miR-145-5p* are known to be located close together on human chromosome 5q32, where they form a cluster \[[@R26]\]. Based on our miRNA signatures, *miR-143* and *miR-145-5p* are the most frequently downregulated miRNAs in various types of human cancers \[[@R26]\]. These two miRNAs have been reported as tumor suppressors and studied extensively for their role in oncogenic pathways in several cancers \[[@R15]\]. Our past studies demonstrated that *hexokinase-2* (*HK2*) and *Golgi membrane protein 1* (*GOLM1*) were directly regulated by *miR-143* and *miR-145-5p* in renal carcinoma and prostate cancer, respectively \[[@R22], [@R23]\].

In this study, we speculated that *miR-145-5p* and *miR-145-3p* worked together to regulate pathways in BC cell progression and metastasis. Our present data showed that *UHRF1* was directly regulated by both *miR-145-5p* and *miR-145-3p* in BC cells. In previous studies of miRNA regulation of *UHRF1* in cancers, *UHRF1* was regulated by *miR-146a*/*146b* in gastric cancer \[[@R27]\], *miR-9* in colorectal cancer \[[@R28]\], and *miR-124* in BC \[[@R29]\]. However, there have been no previous reports about the effects of *miR-145-5p* and *miR-145-3p* on *UHRF1*.

The *UHRF1* gene was first cloned as a transcription factor that binds to the promoter region of the topoisomerase IIα (*TOP2A*) gene and controls its expression levels \[[@R30]\]. UHRF1 is involved in a wide range of physiological and pathological phenomena, including cancer development and metastasis \[[@R31]\]. UHRF1 plays a pivotal role in controlling gene expression through regulating epigenetic mechanisms, including DNA methylation, histone deacetylation, histone methylation, and histone ubiquitination \[[@R31]\]. Overexpression of *UHRF1* occurs in many types of cancer, and aberrantly expressed UHRF1 causes cancer cell activation through hyper-methylation of tumor-suppressor genes such as *BRCA1*, *CDKN2A*, *p73*, and *RASSF1* \[[@R32]\]. Expression of *UHRF1* might be used as a progression marker in cancer \[[@R32]\]. For example, the expression of *UHRF1* in MIBC was greater than in NMIBC, and upregulation was associated with an increased risk of progression after transurethral resection \[[@R33]\]. Our present data showed that knockdown of *UHRF1* significantly induced apoptosis in BC cells and expression levels of the gene correlated with cause specific survival. Our data support the past studies of *UHRF1* in cancer research, suggesting *UHRF1* plays essential roles in BC cell progression and might be a molecular target for BC treatment.

In this study, we identified *UHRF1*-regulated BC pathways by using genome-wide gene expression analysis of *si-UHRF1*-transfected cells. Our expression data showed that *UHRF1* and *TOP2A* were significantly reduced by *si-UHRF1* transfection, indicating the usefulness of the present analytic approach. Our data showed that several anti-apoptosis genes and pro-proliferation genes were involved in pathways downstream of *UHRF1*, such as *BIRC5* and *CENPF*. *BIRC5* is a member of the inhibitor of apoptosis (IAP) family preferentially expressed by many cancers, including BC \[[@R10]\], and its mediated cellular networks are essential for cancer cell proliferation and viability \[[@R34]\]. *CENPF* is a master regulator of prostate cancer malignancy. Together, *FOXM1* and *CENPF* regulate target gene expression and activation in cancer cells \[[@R35], [@R36]\]. The identification of these novel molecular pathways and targets mediated by the *miR-145-5p*/*145-3p*/*UHRF1* axis may lead to a better understanding of BC cell progression and metastasis.

In conclusion, downregulation of dual-strand *miR- 145-5p* and *miR-145-3p* was validated in BC clinical specimens, and these miRNAs were shown to function as tumor suppressors in BC cells. To the best of our knowledge, this is the first report demonstrating that tumor suppressive *miR-145-5p* and *miR-145-3p* directly targeted *UHRF1*. Moreover, *UHRF1* was upregulated in BC clinical specimens and contributed to anti-apoptotic effects through its regulation of several oncogenic genes. Expression of *UHRF1* might be a useful prognostic marker for survival of BC patients. The identification of novel molecular pathways and targets regulated by the *miR-145-5p*/*miR-145-3p*/*UHRF1* axis may lead to a better understanding of BC progression and aggressiveness.

MATERIALS AND METHODS {#s4}
=====================

Clinical specimens and cell lines {#s4_1}
---------------------------------

Clinical tissue specimens were collected from BC patients (*n* = 69) who had undergone transurethral resection of their bladder tumors (TURBT, *n* = 59) or cystectomy (*n* = 10) at Kagoshima University Hospital between 2003 and 2013. NBE (*n* = 12) were derived from patients with noncancerous disease. The specimens were staged according to the American Joint Committee on Cancer-Union Internationale Contre le Cancer tumor-node-metastasis (TNM) classification and histologically graded \[[@R37]\]. Our study was approved by the Bioethics Committee of Kagoshima University; written prior informed consent and approval were obtained from all patients. Patient details and clinicopathological characteristics are listed in Table [6](#T6){ref-type="table"}.

###### Characteristic of patients

  Bladder cancer (BC)                             
  ------------------------------- ---- ---------- --------
  Total number                    69              
  Median age (range)              73   (40--94)   years
  Gender                                          
   Male                           53   76.8%      
   Female                         16   23.2%      
  Tumor grade                                     
   Low grade                      45   65.2%      
   High grade                     22   31.9%      
   Unknown                        2    2.9%       
  T stage                                         
   Tis                            2    2.9%       
   Ta                             7    10.1%      
   T1                             25   36.2%      
   T2                             27   39.1%      
   T3                             4    5.8%       
   T4                             4    5.8%       
  N stage                                         
   N0                             40   58.0%      
   N1                             8    11.6%      
   Unknown                        21   30.4%      
  M stage                                         
   M0                             58   84.1%      
   M1                             5    7.2%       
   Unknown                        6    8.7%       
  Operation method                                
   TURBT                          59   85.5%      
   Cystectomy                     10   14.5%      
  **Normal bladder epithelium**                   
   Total number                   12              
   Median age (range)             61   (47--72)    years

Abbreviation: TURBT = transurethral resection of bladder tumor

We used two human BC cell lines: T24, which was invasive and obtained from the American Type Culture Collection; and BOY, which was established in our laboratory from an Asian male patient, 66 years old, who was diagnosed with stage III BC and lung metastasis \[[@R38], [@R39]\]. These cell lines were maintained in minimum essential medium supplemented with 10% fetal bovine serum in a humidified atmosphere of 5% CO~2~ and 95% air at 37°C.

Tissue collection and RNA extraction {#s4_2}
------------------------------------

Tissues were immersed in RNAlater (Thermo Fisher Scientific; Waltham, MA, USA) and stored at −20°C until RNA extraction was conducted. Total RNA, including miRNA, was extracted using the mirVana^™^ miRNA isolation kit (Thermo Fisher Scientific) following the manufacturer\'s protocol. The integrity of the RNA was checked with an RNA 6000 Nano Assay kit and a 2100 Bioanalyzer (Agilent Technologies, Santa Clara, CA, USA) following the manufacturer\'s protocol.

Quantitative real-time reverse transcription polymerase chain reaction (qRT-PCR) {#s4_3}
--------------------------------------------------------------------------------

The procedure for qRT-PCR quantification was described previously \[[@R40], [@R41]\]. Stem-loop RT-PCR (TaqMan MicroRNA Assays; product ID: 002278 for *miR-145-5p* and product ID: 002149 for *miR-145-3p*; Thermo Fisher Scientific) was used to quantify miRNAs according to previously published conditions \[[@R40]--[@R42]\]. TaqMan probes and primers for *UHRF1* (product ID: Hs 01086727_m1; Thermo Fisher Scientific) were assay-on-demand gene expression products. We used human *GUSB* (product ID: Hs99999908_m1; Thermo Fisher Scientific) and *RNU48* (product ID: 001006; Thermo Fisher Scientific), respectively, as internal controls.

Transfections with miRNA mimic and small interfering RNA (siRNA) into BC cell lines {#s4_4}
-----------------------------------------------------------------------------------

Mature miRNA molecules, Pre-miR^™^ miRNA precursors (*hsa-miR-145-5p*; product ID: PM11480, *hsa-miR-145-3p*; product ID: PM13036, and negative control miRNA; product ID: AM 17111; Thermo Fisher Scientific) were used in the gain-of-function experiments, whereas *UHRF1* siRNA (product ID: HSS120939 and HSS179006; Thermo Fisher Scientific) and negative control siRNA (product ID: D-001810-10; Thermo Fisher Scientific) were used in the loss-of-function experiments. The transfection procedures and transfection efficiencies of miRNA in T24 and BOY cells were reported previously \[[@R40]--[@R42]\].

Cell proliferation, migration, and invasion assays {#s4_5}
--------------------------------------------------

To investigate the functional significance of the *miR-145-5p*, *miR-145-3p*, and *UHRF1*, we performed cell proliferation, migration, and invasion assays using T24 and BOY cells. The experimental procedures were performed as described in our previous studies \[[@R40]--[@R42]\].

Apoptosis assays {#s4_6}
----------------

BC cell lines were transiently transfected with reagent only (mock), miR-control, *miR-145-5p*, *miR- 145- 3p*, siRNA-control, or *si-UHRF1* at 10 nM in 6 well tissue culture plates, as described previously \[[@R14], [@R17]--[@R19]\]. Cells were harvested by trypsinization 72 hours after transfection and washed in cold phosphate-buffered saline. For apoptosis assays, double staining with FITC-Annexin V and propidium iodide was carried out using a FITC Annexin V Apoptosis Detection Kit (BD Biosciences, Bedford, MA, USA) according to the manufacturer\'s recommendations and analysed within 1 hour by flow cytometry (CyAn ADP analyzer; Beckman Coulter, Brea, CA, USA). Cells were identified as viable cells, dead cells, early apoptotic cells, and apoptotic cells using Summit 4.3 software (Beckman Coulter), and the percentages of early apoptotic and apoptotic cells from each experiment were then compared. As a positive control, we used 2 μg/mL cycloheximide.

Cell cycle assays {#s4_7}
-----------------

For the cell cycle analyses, cells were stained with PI using the Cycletest PLUS DNA Reagent Kit (BD Biosciences) following the protocol and analyzed by CyAn ADP analyzer (Beckman Coulter). The percentages of the cells in the G0/G1, S, and G2/M phases were determined and compared. Experiments were performed in triplicate.

Western blot analyses {#s4_8}
---------------------

Immunoblotting was performed with rabbit anti-UHRF1 antibodies (1:500, PA5-29884; Thermo Fisher Scientific), anti-PARP antibodies (1:500 \#9542; Cell Signaling Technology; Danvers, MA, USA), anti-cleaved PARP antibodies (1:500 \#5625; Cell Signaling Technology), and anti-GAPDH antibodies (1:10000 MAB374; Chemicon, Temecula, CA, USA). Specific complexes were visualized with an echochemiluminescence detection system (GE Healthcare, Little Chalfont, UK).

Immunohistochemistry {#s4_9}
--------------------

A tissue microarray of 68 urothelial cancers and 20 normal bladder tissues was obtained from US Biomax, Inc. (Rockville, MD, USA) (product ID: BL1002). Detailed information on all tumor specimens can be found at <http://www.biomax.us/index.php>. The tissue microarray was immunostained following the manufacturer\'s protocol with an Ultra Vision Detection System (Thermo Scientific). The primary rabbit polyclonal antibodies against UHRF1 (PA5-29884; Thermo Fisher Scientific) were diluted 1:300. Immunostaining was evaluated according to a scoring method as described previously \[[@R17]\].

Genome-wide gene expression and *in silico* analyses for the identification of genes regulated by *miR-145-5p* and *miR-145-3p* {#s4_10}
-------------------------------------------------------------------------------------------------------------------------------

To further investigate the specific genes affected by *miR-145-5p* and *miR-145-3p*, we performed a combination of *in silico* and genome-wide gene expression analyses. We attempted to identify target genes using a BC cell line transfected with these miRNAs. A Sure Print G3 Human GE 8 × 60K Microarray (Agilent Technologies) was used for expression profiling of *miR-145-5p* and *miR-145-3p* transfectants. The microarray data were deposited into GEO (<http://www.ncbi.nlm.nih.gov/geo/>) and were assigned GEO accession number GSE66498. Next, we selected putative miRNA target genes using the [microRNA.org](http://microrna.org/) database (August, 2010 release, [http://www.microrna.org](http://www.microrna.org/)). Finally, to identify upregulated genes in BC, we analyzed publicly available gene expression data sets in GEO (accession numbers: GSE11783, GSE31684). The data were normalized and analyzed with Gene Spring software (Agilent Technologies) as described previously \[[@R22], [@R23], [@R40]--[@R42]\]. The strategy for investigation of the target genes is shown in Figure [3](#F3){ref-type="fig"}.

Plasmid construction and dual luciferase reporter assays {#s4_11}
--------------------------------------------------------

Partial wild-type sequences of the 3′ UTR of *UHRF1* or those with a deleted *miR-145-5p* and *miR- 145- 3p* target site (positions 1,179--1,198 of *UHRF1* 3′ UTR for *miR- 145-5p*, and positions 287--292 of *UHRF1* 3′ UTR for *miR-145-3p*) were inserted between the XhoI and PmeI restriction sites in the 3′ UTR of the *hRluc* gene in the psiCHECK-2 vector (C8021; Promega, Madison, WI, USA). T24 and BOY cell lines were transfected with 50 ng of the vector and 10 nM *miR-145-5p* or *miR-145-3p* using Lipofectamine 2000 (Thermo Fisher Scientific) and Opti-MEM (Thermo Fisher Scientific). The activities of firefly and *Renilla* luciferases in cell lysates were determined with a dual luciferase reporter assay system according to the manufacturer\'s protocol (E1960; Promega). Normalized data were calculated as the ratio of *Renilla*/firefly luciferase activities.

Identification of downstream targets regulated by *UHRF1* in BC {#s4_12}
---------------------------------------------------------------

To investigate molecular targets regulated by *UHRF1* in BC cells, we carried out gene expression analyses using *si-UHRF1*-transfected BC cell lines. Microarray data were used for expression profiling of *si-UHRF1* transfectants. The microarray data were deposited into GEO (accession number: GSE77790). We analyzed common down or upregulated genes using the GEO dataset. The flow chart outlining the investigation of *UHRF1* downstream genes is shown in Figure [10A](#F10){ref-type="fig"} and [10B](#F10){ref-type="fig"}.

Statistical analysis {#s4_13}
--------------------

Relationships among two or three variables and numerical values were analysed using the Mann-Whitney *U* test or Bonferroni-adjusted Mann-Whitney *U* test. Spearman\'s rank test was used to evaluate the correlation among the expressions of *miR-145-5p*, *miR-145-3p*, and *UHRF1*. We estimated cause specific survival of 57 BC patients by using the Kaplan-Meier method. Among the 69 BC patients, 12 died of other causes. Therefore, we analyzed cause specific survival of 57 BC patients. Patients were divided into two groups according to the median value of *UHRF1* expression, and the differences between the two groups were evaluated by the log-rank tests. We used Expert Stat View software, version 5.0 (SAS Institute Inc., Cary, NC, USA), for these analyses.

SUPPLEMENTARY MATERIALS FIGURES {#s5}
===============================
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